Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free TYRA Stock Alerts

Tyra Biosciences (TYRA) Financials

Tyra Biosciences logo
$33.93 -1.21 (-3.44%)
Closing price 04:00 PM Eastern
Extended Trading
$35.00 +1.07 (+3.15%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Tyra Biosciences

Annual Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.34 -26 -55 -69 -86 -120
Consolidated Net Income / (Loss)		 -9.34 -26 -55 -69 -86 -120
Net Income / (Loss) Continuing Operations		 -9.34 -26 -55 -69 -86 -120
Total Pre-Tax Income 		-9.34 -26 -55 -69 -86 -120
Total Operating Income		 -9.30 -26 -59 -80 -104 -133
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.30 26 59 80 104 133
Selling, General & Admin Expense		 2.09 5.65 16 17 24 30
Research & Development Expense		 7.20 21 43 63 80 103
Total Other Income / (Expense), net		 -0.04 -0.01 3.60 11 18 13
Interest & Investment Income		 -0.00 0.01 3.65 11 18 13
Basic Earnings per Share		 ($6.05) ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Weighted Average Basic Shares Outstanding		 1.54M 13.78M 41.88M 42.70M 57.22M 59.60M
Diluted Earnings per Share		 ($6.05) ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Weighted Average Diluted Shares Outstanding		 1.54M 13.78M 41.88M 42.70M 57.22M 59.60M
Weighted Average Basic & Diluted Shares Outstanding		 1.54M 13.78M 42.44M 52.52M 53.09M 53.87M

Quarterly Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -21 -22 -18 -19 -24 -27 -28 -28 -30 -34
Consolidated Net Income / (Loss)		 -13 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34
Net Income / (Loss) Continuing Operations		 -13 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34
Total Pre-Tax Income 		-13 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34
Total Operating Income		 -16 -24 -26 -22 -24 -29 -30 -32 -31 -33 -37
Total Operating Expenses		 16 24 26 22 24 29 30 32 31 33 37
Selling, General & Admin Expense		 3.85 4.69 4.96 5.12 5.54 5.91 7.54 6.89 7.14 7.48 8.33
Research & Development Expense		 12 19 21 17 18 23 22 25 24 25 28
Total Other Income / (Expense), net		 2.74 2.81 2.80 4.13 4.83 4.59 4.15 3.70 3.35 3.08 2.68
Interest & Investment Income		 2.74 2.81 2.80 4.13 4.83 4.59 4.15 3.70 3.35 3.08 2.68
Basic Earnings per Share		 ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57)
Weighted Average Basic Shares Outstanding		 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M
Diluted Earnings per Share		 ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57)
Weighted Average Diluted Shares Outstanding		 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M
Weighted Average Basic & Diluted Shares Outstanding		 43.01M 43.06M 52.52M 52.54M 52.81M 50.60M 53.09M 53.18M 53.30M 53.37M 53.87M

Annual Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 15 287 -50 -193 34 -15
Net Cash From Operating Activities		 -7.76 -24 -50 -50 -70 -95
Net Cash From Continuing Operating Activities		 -7.76 -24 -50 -50 -70 -95
Net Income / (Loss) Continuing Operations		 -9.34 -26 -55 -69 -86 -120
Consolidated Net Income / (Loss)		 -9.34 -26 -55 -69 -86 -120
Depreciation Expense		 0.05 0.14 0.30 0.36 0.52 0.55
Non-Cash Adjustments To Reconcile Net Income		 0.46 2.89 11 12 17 26
Changes in Operating Assets and Liabilities, net		 1.07 -0.48 -5.85 6.36 -0.73 -1.63
Net Cash From Investing Activities		 -0.31 -0.65 -0.56 -145 -98 72
Net Cash From Continuing Investing Activities		 -0.31 -0.65 -0.56 -145 -98 72
Purchase of Property, Plant & Equipment		 -0.31 -0.66 -0.56 -0.77 -0.66 -0.14
Purchase of Investments		 - - 0.00 -144 -264 -101
Sale and/or Maturity of Investments		 - - 0.00 0.00 166 174
Net Cash From Financing Activities		 23 311 0.63 1.54 202 8.10
Net Cash From Continuing Financing Activities		 23 311 0.63 1.54 202 8.10
Issuance of Common Equity		 0.14 182 0.63 1.54 202 8.10

Quarterly Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -9.29 -17 -158 196 -155 4.40 -12 8.76 -2.23 -37 15
Net Cash From Operating Activities		 -9.62 -17 -14 -22 -10 -18 -20 -25 -24 -22 -24
Net Cash From Continuing Operating Activities		 -9.62 -17 -14 -22 -10 -18 -20 -25 -24 -22 -24
Net Income / (Loss) Continuing Operations		 -13 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34
Consolidated Net Income / (Loss)		 -13 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34
Depreciation Expense		 0.09 0.08 0.10 0.12 0.13 0.13 0.14 0.14 0.14 0.13 0.13
Non-Cash Adjustments To Reconcile Net Income		 2.53 4.38 2.94 2.89 2.54 5.97 5.52 5.56 5.67 7.16 7.50
Changes in Operating Assets and Liabilities, net		 1.04 -0.45 6.26 -6.84 5.77 0.02 0.32 -3.01 -1.39 0.20 2.58
Net Cash From Investing Activities		 -0.04 -0.08 -144 18 -145 22 6.96 32 21 -15 34
Net Cash From Continuing Investing Activities		 -0.04 -0.08 -144 18 -145 22 6.96 32 21 -15 34
Purchase of Property, Plant & Equipment		 -0.04 -0.08 -0.60 -0.14 -0.47 -0.05 -0.01 -0.01 -0.03 -0.04 -0.06
Purchase of Investments		 - - -144 -12 -177 -36 -38 -6.87 -20 -65 -9.11
Sale and/or Maturity of Investments		 - - - 30 33 58 45 39 41 50 44
Net Cash From Financing Activities		 0.37 0.47 0.32 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68
Net Cash From Continuing Financing Activities		 0.37 0.47 0.32 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68
Issuance of Common Equity		 0.37 0.47 0.32 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68

Annual Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 307 266 226 364 283
Total Current Assets		 15 304 257 212 347 265
Cash & Equivalents		 15 302 251 58 92 77
Short-Term Investments		 - - 0.00 145 249 179
Prepaid Expenses		 0.06 1.88 6.08 8.20 6.02 9.45
Plant, Property, & Equipment, net		 0.30 1.03 1.08 1.63 1.65 1.31
Total Noncurrent Assets		 0.43 1.62 7.82 13 14 16
Other Noncurrent Operating Assets		 0.43 1.62 7.82 13 14 16
Total Liabilities & Shareholders' Equity		 16 307 266 226 364 283
Total Liabilities		 2.00 4.96 8.35 22 20 23
Total Current Liabilities		 1.86 3.62 5.70 15 15 18
Accounts Payable		 0.66 0.60 1.15 4.66 0.59 1.18
Accrued Expenses		 1.05 2.82 4.42 10 14 16
Other Current Liabilities		 0.14 0.20 0.14 0.28 0.41 0.47
Total Noncurrent Liabilities		 0.14 1.35 2.65 6.26 5.81 5.34
Other Noncurrent Operating Liabilities		 0.14 1.35 2.65 6.26 5.81 5.34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -14 302 258 204 343 259
Total Preferred & Common Equity		 -14 302 258 204 343 259
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -14 302 258 204 343 259
Common Stock		 0.44 342 354 369 594 630
Retained Earnings		 -14 -40 -96 -165 -251 -371
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.38 0.77 0.39

Quarterly Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 276 255 250 238 405 392 381 343 321 302
Total Current Assets		 267 247 241 225 391 379 366 325 302 281
Cash & Equivalents		 263 242 232 216 254 99 104 101 98 62
Short-Term Investments		 - - - - 128 274 256 218 198 213
Prepaid Expenses		 4.26 5.01 8.33 8.98 8.32 4.78 5.48 5.62 5.88 6.29
Plant, Property, & Equipment, net		 1.15 1.05 1.05 1.15 1.59 1.90 1.79 1.52 1.41 1.35
Total Noncurrent Assets		 7.37 7.30 8.21 13 12 12 13 17 18 19
Other Noncurrent Operating Assets		 7.37 7.30 8.21 13 12 12 13 17 18 19
Total Liabilities & Shareholders' Equity		 276 255 250 238 405 392 381 343 321 302
Total Liabilities		 8.23 6.27 11 16 15 16 18 20 19 21
Total Current Liabilities		 5.49 3.68 5.41 10 8.72 10 12 14 14 16
Accounts Payable		 2.75 1.28 1.44 2.31 2.88 1.58 1.17 2.50 2.25 1.99
Accrued Expenses		 2.62 2.26 3.82 7.69 5.47 8.42 11 11 11 13
Other Current Liabilities		 0.13 0.14 0.14 0.15 0.37 0.38 0.40 0.43 0.44 0.46
Total Noncurrent Liabilities		 2.74 2.58 6.04 6.04 6.15 6.04 5.93 5.70 5.58 5.46
Other Noncurrent Operating Liabilities		 2.74 2.58 6.04 6.04 6.15 6.04 5.93 5.70 5.58 5.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 268 249 239 222 390 376 362 324 302 281
Total Preferred & Common Equity		 268 249 239 222 390 376 362 324 302 281
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 268 249 239 222 390 376 362 324 302 281
Common Stock		 351 356 359 364 573 578 586 602 609 617
Retained Earnings		 -83 -108 -121 -142 -183 -202 -226 -279 -308 -337
Accumulated Other Comprehensive Income / (Loss)		 - - - - -0.01 -0.18 1.75 0.69 0.44 0.44

Annual Metrics And Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 41,265,756.00 - - - 53,372,098.00
DEI Adjusted Shares Outstanding		 0.00 41,265,756.00 - - - 53,372,098.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.64 - - - -2.25
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.51 -18 -41 -56 -73 -93
Return On Investment Capital (ROIC_SIMPLE)		 - - - -27.40% -21.25% -35.86%
Earnings before Interest and Taxes (EBIT)		 -9.34 -26 -59 -80 -104 -133
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.29 -26 -59 -80 -104 -132
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -48 -50 -74 -94
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.21 -0.45 6.62 0.79 1.71 3.17
Increase / (Decrease) in Invested Capital		 0.00 0.77 7.06 -5.82 0.92 1.46
Book Value per Share		 ($8.84) $7.31 $6.11 $4.74 $6.78 $4.86
Tangible Book Value per Share		 ($8.84) $7.31 $6.11 $4.74 $6.78 $4.86
Total Capital		 14 302 258 204 343 259
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -302 -251 -203 -341 -256
Capital Expenditures (CapEx)		 0.31 0.65 0.56 0.77 0.66 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.80 -1.74 0.37 -7.13 -8.57 -8.65
Debt-free Net Working Capital (DFNWC)		 13 300 252 196 333 247
Net Working Capital (NWC)		 13 300 252 196 333 247
Net Nonoperating Expense (NNE)		 2.83 7.89 14 13 14 27
Net Nonoperating Obligations (NNO)		 -15 -302 -251 -203 -341 -256
Total Depreciation and Amortization (D&A)		 0.05 0.14 0.30 0.36 0.52 0.55
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.60M 41.88M 42.70M 57.22M 59.60M
Adjusted Diluted Earnings per Share		 $0.00 ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.60M 41.88M 42.70M 57.22M 59.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.91) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.78M 42.44M 52.52M 53.09M 53.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.51 -18 -41 -56 -73 -93
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - 53,089,957.00 53,177,990.00 53,297,140.00 53,372,098.00
DEI Adjusted Shares Outstanding		 - - - - - - - 53,089,957.00 53,177,990.00 53,297,140.00 53,372,098.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.53 -0.53 -0.56 -0.63
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -11 -17 -18 -16 -16 -20 -21 -22 -22 -23 -26
Return On Investment Capital (ROIC_SIMPLE)		 - - -8.78% - - - -6.06% -6.89% -7.29% -8.22% -9.86%
Earnings before Interest and Taxes (EBIT)		 -16 -24 -26 -22 -24 -29 -30 -32 -31 -33 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -24 -26 -22 -23 -28 -30 -32 -31 -33 -36
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -19 -12 -16 -13 -16 -22 -19 -26 -26 -27
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.16 6.52 0.79 7.42 2.25 2.16 1.71 4.59 5.88 5.59 3.17
Increase / (Decrease) in Invested Capital		 2.41 1.97 -5.82 0.33 -3.91 -4.36 0.92 -2.83 3.63 3.43 1.46
Book Value per Share		 $5.61 $5.17 $4.74 $7.42 $7.16 $6.86 $6.78 $6.09 $5.68 $5.26 $4.86
Tangible Book Value per Share		 $5.61 $5.17 $4.74 $7.42 $7.16 $6.86 $6.78 $6.09 $5.68 $5.26 $4.86
Total Capital		 239 222 204 390 376 362 343 324 302 281 259
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -232 -216 -203 -382 -374 -360 -341 -319 -296 -275 -256
Capital Expenditures (CapEx)		 0.04 0.08 0.60 0.14 0.47 0.05 0.01 0.01 0.03 0.04 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.93 -1.17 -7.13 -0.40 -5.60 -6.89 -8.57 -8.62 -7.89 -9.59 -8.65
Debt-free Net Working Capital (DFNWC)		 235 214 196 382 368 353 333 310 288 265 247
Net Working Capital (NWC)		 235 214 196 382 368 353 333 310 288 265 247
Net Nonoperating Expense (NNE)		 2.06 4.38 4.89 2.57 2.23 3.99 4.77 5.85 6.08 6.81 8.27
Net Nonoperating Obligations (NNO)		 -232 -216 -203 -382 -374 -360 -341 -319 -296 -275 -256
Total Depreciation and Amortization (D&A)		 0.09 0.08 0.10 0.12 0.13 0.13 0.14 0.14 0.14 0.13 0.13
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57)
Adjusted Weighted Average Basic Shares Outstanding		 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M
Adjusted Diluted Earnings per Share		 ($0.31) ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57)
Adjusted Weighted Average Diluted Shares Outstanding		 42.59M 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.01M 43.06M 52.52M 52.54M 52.81M 50.60M 53.09M 53.18M 53.30M 53.37M 53.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -17 -18 -16 -16 -20 -21 -22 -22 -23 -26
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Tyra Biosciences (TYRA) continues to operate without revenue, posting meaningful net losses and cash burn. The company has relied on equity financing and investment activity to fund its R&D programs, and 2025 shows both liquidity support and ongoing fundraising. Below are the key trends drawn from quarterly statements over the past four years, focused on liquidity, capital activity, and profitability signals for retail investors.

  • Liquidity: As of 2025 Q3, Tyra held about $61.95M in cash and $212.97M in short-term investments, totaling roughly $274.9M of readily available liquidity on the balance sheet.
  • Ongoing equity financing: In 2025, Tyra raised roughly $8.1M in net proceeds from common stock issuances across Q1–Q4 2025 (Q1: $2.19M; Q2: $0.58M; Q3: $0.65M; Q4: $4.68M).
  • Investing activity inflows: Tyra has benefited from sizable cash inflows from sale/maturity of investments in several quarters, including Q2 2025 ($41.00M), Q3 2025 ($50.41M), and Q4 2025 ($43.54M), which bolster liquidity during periods of negative operating cash flow.
  • Net financing activity: In select quarters, net financing activity contributed to liquidity (e.g., Q4 2025 net financing activity around $4.68M; Q1 2025 around $2.19M), helping support cash on hand during funding gaps.
  • Balance sheet strength: Total assets around $301.9M (2025 Q3), with total liabilities about $21.3M and total equity around $280.5M, indicating a sizable equity base and relatively light leverage vs. assets.
  • Revenue status: Tyra remains pre-revenue in many quarters, with Total Revenue reported as $0 in Q4 2025 and in several prior periods, reflecting a development-stage biotech profile rather than a sales-driven model.
  • Dilution risk: Continued equity issuances and a relatively high share count contribute to potential dilution concerns; 2025 quarters show weighted-average basic/diluted shares in the 59–60 million range for 2025 Q4, producing negative EPS despite no revenue.
  • Persistent net losses: Net income attributable to common shareholders in 2025 Q4 is -$33.834M; 2025 Q3 is -$29.868M; Q2 is -$28.098M; Q1 is -$28.147M, highlighting ongoing losses as funds are directed to R&D and clinical programs.
  • Operating cash burn: Net cash from operating activities remained negative across observed 2025 quarters (e.g., Q4 2025: -$23.624M; Q3 2025: -$22.38M; Q2 2025: -$23.68M; Q1 2025: -$25.46M), indicating a continued need for external funding.
  • Deficit in retained earnings: Retained earnings are deeply negative (e.g., Q4 2025 balance sheet Retained Earnings: -$337.424M), reflecting accumulated losses that must be funded through future financing or equity value realization.
05/05/26 06:01 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Tyra Biosciences' Financials

When does Tyra Biosciences' financial year end?

According to the most recent income statement we have on file, Tyra Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Tyra Biosciences' net income changed over the last 5 years?

Tyra Biosciences' net income appears to be on an upward trend, with a most recent value of -$119.95 million in 2025, rising from -$9.34 million in 2020. The previous period was -$86.48 million in 2024. Check out Tyra Biosciences' forecast to explore projected trends and price targets.

What is Tyra Biosciences' operating income?
Tyra Biosciences' total operating income in 2025 was -$132.76 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $132.76 million
How has Tyra Biosciences' revenue changed over the last 5 years?

Over the last 5 years, Tyra Biosciences' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

How much debt does Tyra Biosciences have?

Tyra Biosciences' total liabilities were at $23.43 million at the end of 2025, a 14.8% increase from 2024, and a 1,072.8% increase since 2020.

How much cash does Tyra Biosciences have?

In the past 5 years, Tyra Biosciences' cash and equivalents has ranged from $15.22 million in 2020 to $302.18 million in 2021, and is currently $77.39 million as of their latest financial filing in 2025.

How has Tyra Biosciences' book value per share changed over the last 5 years?

Over the last 5 years, Tyra Biosciences' book value per share changed from -8.84 in 2020 to 4.86 in 2025, a change of -154.9%.


Related Companies

Financial statements for NASDAQ:TYRA last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey ...
Banyan Hill Publishing | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel